We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Advice on Labeling, Advertising Biologics Updated in Revised Draft Guidance
FDA Advice on Labeling, Advertising Biologics Updated in Revised Draft Guidance
Answers to questions biologics companies may have when developing promotional communications for prescription biologics including reference products, biosimilars, and interchangeable biosimilars have been issued by the FDA in a revised draft guidance.